CORONA Remedies Limited
(Formerly known as CORONA Remedies Private Limited)
Regd. Office: CORONA House
C- Mondeal Business Park, Near Gurudwara, S.G. Highway,
Thaltej, Ahmedabad 380 059. Gujarat, India.
Tele.: +079 - 40233000
Online at : Info@coronaremedies.com
website : www.coronaremedies.com
CIN : L24231GJ2004PLC044656

January 02, 2026

To,
Listing Operation Department
BSE Limited
P. J. Towers,
Dalal Street, Mumbai - 400001
(BSE Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla
Complex, Bandra (East), Mumbai– 400051
(NSE Scrip Code: CORONA)

Dear Sir / Madam,

Sub.: Unaudited financial results along with the limited review reports for second quarter and half year ended September 30, 2025
Ref.: Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, find enclosed herewith the unaudited financial results of the Company for the second quarter and half year ended September 30, 2025, along with the limited review reports issued by Deloitte Haskins & Sells LLP, Statutory Auditors of the Company, approved by the Board of Directors at its meeting held today i.e., Friday, January 02, 2026.

The above results along with limited review reports are also being made available on the website of the Company at www.coronaremedies.com

The Board meeting commenced at 03:30 p.m. and concluded at 4:30 p.m.

You are requested to take note of the above.

Thanking you.

Yours Faithfully,

For **CORONA Remedies Limited**

CHETNA PRABHAT KUMAR DHARAJIYA
Digitally signed by CHETNA PRABHAT KUMAR DHARAJIYA
Date: 2026.01.02 18:50:47 +05'30'

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a

Deloitte
Haskins & Sells LLP

Chartered Accountants
19th Floor, Shapath-V
S.G. Highway
Ahmedabad - 380 015
Gujarat, India

Tel: +91 79 6682 7300
Fax: +91 79 6682 7400

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CORONA REMEDIES LIMITED (FORMERLY KNOWN AS CORONA REMEDIES PRIVATE LIMITED)

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited)** ("the Company"), for the quarter and half year ended September 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



5. As stated in Note 4 to the Statement, financial information relating to the quarter and half year ended September 30, 2024 included in the Statement have been furnished to us by the Management and have not been subjected to review by us.

   Our conclusion on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



H. S. Sutaria

Hardik Sutaria
Partner
Membership No. 116642
UDIN: 26116642FIGOUY9493

Place: Ahmedabad
Date: January 02, 2026

CORONA Remedies Limited
(formerly known as CORONA Remedies Private Limited)
Regd. Office: CORONA House,
C - Mondeal Business Park, Near Gurudwara, S.G.Highway,
Thaltej, Ahmedabad-380059, Gujarat, India
Tele.: +079-40233000 | Website : www.coronaremedies.com
CIN : L24231GJ2004PLC044656

Statement of Unaudited Standalone Financial Results for the Quarter and Half Year ended 30 September 2025

(Amount Rs. in Crores except per share data)

Sr. No.	Particulars	For Quarter Ended			For Half Year Ended		For Year Ended
		30 Sept. 2025 (Unaudited)	30 June 2025 (Audited) (Refer note 5)	30 Sept. 2024 (Unaudited) (Refer note 4)	30 Sept. 2025 (Unaudited)	30 Sept. 2024 (Unaudited) (Refer note 4)	31 March 2025 (Audited)
1	**Income :**						
a	Revenue from operations	361.13	346.54	313.87	707.67	605.04	1,196.42
b	Other income	2.27	2.02	2.46	4.29	3.75	5.93
	Total income	**363.40**	**348.56**	**316.33**	**711.96**	**608.79**	**1,202.35**
2	**Expenses :**						
a	Cost of materials consumed	25.90	25.07	28.56	50.97	51.69	102.29
b	Purchases of Stock-in-trade	28.11	34.77	41.94	62.88	77.02	157.97
c	Changes in inventories of finished goods, stock-in-trade and work-in-progress	14.64	5.94	(7.90)	20.58	(4.25)	(23.74)
d	Employee benefits expense	103.00	97.44	87.82	200.44	171.82	346.14
e	Finance costs	1.93	1.99	2.87	3.92	6.02	10.60
f	Depreciation and amortization expenses	9.20	8.92	9.05	18.12	17.43	37.16
g	Other expenses	111.01	113.54	96.63	224.55	192.42	373.78
	Total expenses	**293.79**	**287.67**	**258.97**	**581.46**	**512.15**	**1,004.20**
3	**Profit before tax (1-2)**	**69.61**	**60.89**	**57.36**	**130.50**	**96.64**	**198.15**
4	**Tax expense :**						
a	Current tax expense	15.85	15.19	12.89	31.04	22.22	45.55
b	(Excess) provision for tax relating to earlier periods / year	-	(0.89)	(0.75)	(0.89)	(0.75)	(0.75)
c	Deferred tax expense / (income)	1.61	0.19	2.24	1.80	2.24	4.30
	Total Tax expense	**17.46**	**14.49**	**14.38**	**31.95**	**23.71**	**49.10**
5	**Net Profit after tax for the period / year (3-4)**	**52.15**	**46.40**	**42.98**	**98.55**	**72.93**	**149.05**
6	**Other comprehensive income / (loss) for the period/year**						
a	Items that will not be reclassified to profit and loss	0.41	(1.08)	(0.58)	(0.67)	(0.58)	(1.16)
b	Income tax effect on above item	(0.10)	0.27	0.15	0.17	0.15	0.29
	Other comprehensive income / (loss) for the period/year	**0.31**	**(0.81)**	**(0.43)**	**(0.50)**	**(0.43)**	**(0.87)**
7	**Total comprehensive income for the period/year (5+6)**	**52.46**	**45.59**	**42.55**	**98.05**	**72.50**	**148.18**
8	Paid-up equity share capital (face value Rs.10/-)	61.16	61.16	61.16	61.16	61.16	61.16
9	Other Equity						544.56
10	**Earnings per share (not annualised for the quarter and half year)**						
a	Basic (Rs.)	8.53	7.59	7.03	16.11	11.92	24.37
b	Diluted (Rs.)	8.53	7.59	7.03	16.11	11.92	24.37

For Identification Purposes Only * DELOITTE HASKINS & SELLS LLP * CHARTERED ACCOUNTANTS * MUMBAI

CORONA Remedies Limited AHMEDABAD

Unaudited Statement of Standalone Assets and Liabilities as at 30 September 2025
(Amount Rs. in Crores)

Sr. No.	Particulars	As at 30 Sept. 2025 (Unaudited)	As at 31 March 2025 (Audited)
A	**ASSETS:**		
1	**Non-current assets**		
a	Property, plant and equipment	200.12	198.73
b	Capital work-in-progress	204.81	185.95
c	Other intangible assets	167.98	171.15
d	Financial assets		
i	Investments	25.37	25.34
ii	Loans	0.01	0.03
iii	Other financial assets	27.23	1.25
e	Other non-current assets	4.63	7.92
	Total non-current assets	630.15	590.37
2	**Current assets**		
a	Inventories	107.30	129.48
b	Financial assets		
i	Trade receivables	160.08	118.29
ii	Cash and cash equivalents	1.80	3.22
iii	Bank balances other than cash and cash equivalents	52.16	66.05
iv	Loans	0.19	0.38
v	Other financial assets	11.10	2.64
c	Other current assets	13.23	18.81
	Total current assets	345.86	338.87
	TOTAL ASSETS	**976.01**	**929.24**
B	**EQUITY AND LIABILITIES:**		
1	**Equity**		
a	Equity share capital	61.16	61.16
b	Other equity	597.90	544.56
	Total equity	659.06	605.72
	Liabilities		
2	**Non-current liabilities**		
a	Financial liabilities		
i	Borrowings	-	16.00
ii	Lease liabilities	20.28	21.02
b	Provisions	44.36	38.61
c	Deferred tax liabilities (net)	9.93	8.30
	Total non-current liabilities	74.57	83.93
3	**Current liabilities**		
a	Financial liabilities		
i	Borrowings	39.58	46.70
ii	Lease liabilities	2.85	2.52
iii	Trade payables		
	- total outstanding dues of micro enterprises and small enterprises	6.83	2.91
	- total outstanding dues of creditors other than micro enterprise and small enterprise	133.92	140.61
iv	Other financial liabilities	4.67	4.77
b	Other current liabilities	10.66	8.37
c	Provisions	30.00	27.39
d	Current tax liabilities (net)	13.87	6.32
	Total current liabilities	242.38	239.59
	Total liabilities	316.95	323.52
	TOTAL EQUITY AND LIABILITIES	**976.01**	**929.24**

For Identification Purposes Only * DELOITTE HASKINS & SELLS LLP * CHARTERED ACCOUNTANTS * For Identification Purposes Only
MUMBAI
CORONA Remedies Limited
AHMEDABAD

Unaudited Statement of Standalone Cash Flows for the Half Year ended 30 September 2025
(Amount Rs. in Crores)

Particulars	For Half Year ended Sept.2025 (Unaudited)	For Half Year ended Sept.2024 (Unaudited) (Refer note 4)
Cash flow from operating activities		
Profit before tax	130.50	96.64
Adjustments for:		
Depreciation and amortization expenses	18.12	17.43
Finance costs	3.92	6.02
Interest income	(2.76)	(2.75)
Fair valuation adjustments of Investments designated as Fair Value through Profit & Loss (FVTPL)	(0.04)	(0.01)
Loss on sale/disposal of fixed assets	0.43	0.06
Provision for expected credit loss*	0.05	0.00
Provision for inventory obsolescence written back	(1.03)	(0.47)
Bad debts written off	0.05	0.01
Liabilities written back	(0.06)	(0.12)
Provision for expiry and breakage sales return	4.83	4.11
Net Unrealized exchange Gain	(0.24)	(0.04)
Operating profit before working capital changes	**153.77**	**120.88**
Changes in working capital		
Decrease/ (Increase) in inventories	23.22	(8.30)
Increase in trade receivables	(41.66)	(26.77)
Decrease / (Increase) in other current assets	5.58	(0.36)
Increase in other financial assets	(8.51)	(0.12)
Decrease in non-current assets	0.04	0.15
Decrease in loans	0.21	0.24
Increase in other financial liabilities	0.96	0.64
Increase in provisions	2.86	1.51
(Decrease) / Increase in trade payables	(2.72)	25.26
Increase in other current liabilities	2.29	7.28
Cash generated from operations	**136.04**	**120.41**
Income taxes paid (Net)	(22.60)	(15.64)
Net cash generated from operating activities (A)	**113.44**	**104.77**
Cash flow from Investing activities		
Payment for property, plant and equipment and intangible assets including capital work-in-progress, capital advance and capital payable	(32.51)	(40.80)
Proceeds from sale/ disposal of fixed assets	0.47	0.20
Fixed deposits placed with Bank not considered as Cash and cash equivalents-Net	(12.04)	15.31
Interest received	2.76	2.75
Net cash (used in) investing activities (B)	**(41.32)**	**(22.54)**
Cash flow from Financing activities		
Payment of dividend	(44.71)	(22.63)
Repayment of long-term borrowings	(18.00)	(33.00)
Net decrease in working capital borrowings	(5.11)	(19.87)
Interest paid	(3.27)	(4.84)
Payment towards lease liability (excluding interest)	(1.37)	(1.14)
Interest on lease liability	(1.09)	(1.18)
Net cash (used in) from financing activities (C)	**(73.55)**	**(82.66)**
Net (decrease) in cash and cash equivalents (A+B+C)	**(1.43)**	**(0.43)**
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents**	0.01	0.00
Cash and cash equivalents at the beginning of the period	**3.22**	**3.16**
Cash and cash equivalents at the end of the period	**1.80**	**2.73**

* Provision for expected credit loss for half year ended September 2024 represents amounting Rs.30,000/-

**Effect of exchange differences on restatement of foreign currency Cash and cash equivalents for half year ended September 2024 represents amounting Rs.33,835/-

Particulars	For Half Year ended Sept.2025 (Unaudited)	For Half Year ended Sept.2024 (Unaudited) (Refer note 4)
Cash and cash equivalents comprise		
Balances with banks:		
In current accounts	0.30	0.24
Cheques on hand	1.45	2.29
Cash on hand	0.05	0.20
Total cash and bank balances at end of the period	**1.80**	**2.73**

For Identification Purposes Only
DELOITTE HASKINS & SELLS LLP
CHARTERED ACCOUNTANTS
MUMBAI
CORONA Remedies Limited
AHMEDABAD

Notes to unaudited standalone financial results for the Quarter and Half Year ended 30 September 2025 :

1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders.

As the Company's equity shares were listed on 15 December 2025, this statement of unaudited standalone financial results for the quarter and half year ended 30 September 2025 is prepared for the first time in compliance with Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.

2 The above unaudited standalone financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 02 January 2026. The Statutory Auditors have carried out limited review of the aforesaid results.

3 These unaudited standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.

4 The financial results for the quarter ended 30 September 2024 and the half year ended 30 September 2024 have not been subject to limited review. However the management has exercised necessary diligence to ensure that the financial results for those periods provide a true and fair view of the Company's affairs.

5 The standalone financial results for the quarter ended 30 June 2025 have been extracted from the audited special purpose interim financial statements which were prepared for IPO filings.

6 The Company has only one reportable business segment i.e. 'Pharmaceuticals'.

7 The Ministry of Labour& Employment (MoLE), Government of India, has announced the implementation of four Labour Codes viz. the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (Collectively "The Labour Codes"), effective 21 November 2025. The Company is in the process of assessing the impact of such changes. Since the Labour Codes are effective from 21 November 2025, they do not have any implication on the results for the quarter and half year ended 30 September 2025.

For CORONA Remedies Limited,

Nirav K. Mehta
Managing Director & CEO
DIN : 01644041

Place: Ahmedabad
Date : 02 January 2026

CORONA Remedies Limited AHMEDABAD

For Identification Purposes Only * DELOITTE HASKINS & SELLS LLP * CHARTERED ACCOUNTANTS * MUMBAI * For Identification Purposes Only

Deloitte
Haskins & Sells LLP

Chartered Accountants
19th Floor, Shapath-V
S.G. Highway
Ahmedabad - 380 015
Gujarat, India

Tel: +91 79 6682 7300
Fax: +91 79 6682 7400

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CORONA REMEDIES LIMITED (FORMELY KNOWN AS CORONA REMEDIES PRIVATE LIMITED)

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited)** ("the Parent") and its share of the net profit/(loss) after tax and total comprehensive income/(loss) of its associate for the quarter and half year ended September 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes the results of the following entities:
   a) CORONA Remedies Limited (formerly known as CORONA Remedies Private Limited) - Parent
   b) La Chandra Pharma Labs Private Limited - Associate

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The unaudited consolidated financial results include the Parent's share of profit/(loss) after tax of Rs 0.17 Crores and Rs (0.03) Crores for the quarter and half year ended September 30, 2025 respectively and total comprehensive income/(loss) of Rs.0.17 Crores and Rs (0.03) Crores for the quarter and half year ended September 30, 2025 respectively, as considered in the Statement, in respect of 1 associate, based on their interim financial information which have not been reviewed by its auditor. According to the information and explanations given to us by the Management, this interim financial information is not material to the unaudited consolidated financial results.

   Our conclusion on the Statement is not modified in respect of our reliance on the financial information certified by the Management.

7. As stated in Note 4 to the Statement, financial information relating to the quarter and half year ended September 30, 2024 included in the Statement have been furnished to us by the Management and have not been subjected to review by us.

   Our conclusion on the Statement is not modified in respect of this matter.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

DELOITTE HASKINS & SELLS LLP * CHARTERED ACCOUNTANTS *

H. S. Sutaria

Hardik Sutaria
Partner
Membership No. 116642
UDIN: 26116642NREZGK6570

Place: Ahmedabad
Date: January 02, 2026

CORONA Remedies Limited
(formerly known as CORONA Remedies Private Limited)
Regd. Office: CORONA House,
C - Mondeal Business Park, Near Gurudwara, S.G.Highway,
Thaltej, Ahmedabad-380059, Gujarat, India
Tele.: +079-40233000 | Website : www.coronaremedies.com
CIN : L24231GJ2004PLC044656

Statement of Unaudited Consolidated Financial Results for the Quarter and Half Year ended 30 September 2025

(Amount Rs. in Crores except per share data)

Sr. No.	Particulars	For Quarter Ended			For Half Year Ended		For Year Ended
		30 Sept. 2025 (Unaudited)	30 June 2025 (Audited) (Refer note 5)	30 Sept. 2024 (Unaudited) (Refer note 4)	30 Sept. 2025 (Unaudited)	30 Sept. 2024 (Unaudited) (Refer note 4)	31 March 2025 (Audited)
1	**Income :**						
a	Revenue from operations	361.13	346.54	313.87	707.67	605.04	1,196.42
b	Other income	2.27	2.02	2.46	4.29	3.75	5.93
	Total income	**363.40**	**348.56**	**316.33**	**711.96**	**608.79**	**1,202.35**
2	**Expenses :**						
a	Cost of materials consumed	25.90	25.07	28.56	50.97	51.69	102.29
b	Purchases of Stock-in-trade	28.11	34.77	41.94	62.88	77.02	157.97
c	Changes in inventories of finished goods, stock-in-trade and work-in-progress	14.64	5.94	(7.90)	20.58	(4.25)	(23.74)
d	Employee benefits expense	103.00	97.44	87.82	200.44	171.82	346.14
e	Finance costs	1.93	1.99	2.87	3.92	6.02	10.60
f	Depreciation and amortization expenses	9.20	8.92	9.05	18.12	17.43	37.16
g	Other expenses	111.01	113.54	96.63	224.55	192.42	373.78
	Total expenses	**293.79**	**287.67**	**258.97**	**581.46**	**512.15**	**1,004.20**
3	**Profit before tax and share of profit of Associate (1-2)**	**69.61**	**60.89**	**57.36**	**130.50**	**96.64**	**198.15**
4	Share of Profit / (Loss) of Associate (net of tax)	0.17	(0.20)	(0.01)	(0.03)	(0.01)	0.38
5	**Profit before tax (3+4)**	**69.78**	**60.69**	**57.35**	**130.47**	**96.63**	**198.53**
6	**Tax expense :**						
a	Current tax expense	15.85	15.19	12.89	31.04	22.22	45.55
b	(Excess) provision for tax relating to earlier periods / year	-	(0.89)	(0.75)	(0.89)	(0.75)	(0.75)
c	Deferred tax expense / (income)	1.61	0.19	2.24	1.80	2.24	4.30
	Tax expense	**17.46**	**14.49**	**14.38**	**31.95**	**23.71**	**49.10**
7	**Net Profit after tax for the period / year (5-6)**	**52.32**	**46.20**	**42.97**	**98.52**	**72.92**	**149.43**
8	**Other comprehensive income / (loss) for the period/year**						
a	Items that will not be reclassified to profit and loss	0.41	(1.08)	(0.58)	(0.67)	(0.58)	(1.16)
b	Income tax effect on above item	(0.10)	0.27	0.15	0.17	0.15	0.29
	Other comprehensive income / (loss) for the period/year	**0.31**	**(0.81)**	**(0.43)**	**(0.50)**	**(0.43)**	**(0.87)**
9	**Total comprehensive income for the period/year (7+8)**	**52.63**	**45.39**	**42.54**	**98.02**	**72.49**	**148.56**
10	**Profit for the year/period attributable to:**						
	Owners of the Company	52.32	46.20	42.97	98.52	72.92	149.43
		52.32	**46.20**	**42.97**	**98.52**	**72.92**	**149.43**
11	**Total Other Comprehensive (loss) for the period/year attributable to:**						
	Owners of the Company	0.31	(0.81)	(0.43)	(0.50)	(0.43)	(0.87)
		0.31	**(0.81)**	**(0.43)**	**(0.50)**	**(0.43)**	**(0.87)**
12	**Total Comprehensive Income for the period/year attributable to:**						
	Owners of the Company	52.63	45.39	42.54	98.02	72.49	148.56
		52.63	**45.39**	**42.54**	**98.02**	**72.49**	**148.56**
13	Paid-up equity share capital (face value Rs.10/-)	61.16	61.16	61.16	61.16	61.16	61.16
14	Other Equity						545.18
15	**Earnings per share (not annualised for the quarter and half year)**						
a	Basic (Rs.)	8.55	7.55	7.03	16.11	11.92	24.43
b	Diluted (Rs.)	8.55	7.55	7.03	16.11	11.92	24.43

For Identification Purposes Only
DELOITTE HASKINS & SELLS LLP
CHARTERED ACCOUNTANTS
MUMBAI
For Identification Purposes Only

CORONA Remedies Limited
AHMEDABAD

Unaudited Statement of Consolidated Assets and Liabilities as at 30 September 2025
(Amount Rs. in Crores)

Sr. No.	Particulars	As at 30 Sept. 2025 (Unaudited)	As at 31 March 2025 (Audited)
A	**ASSETS:**		
1	**Non-current assets**		
a	Property, plant and equipment	200.12	198.73
b	Capital work-in-progress	204.81	185.95
c	Other intangible assets	167.98	171.15
e	Investments accounted using equity method	25.82	25.85
f	Financial assets		
i	Investments	0.14	0.11
ii	Loans	0.01	0.03
iii	Other financial assets	27.23	1.25
g	Other non-current assets	4.63	7.92
	Total non-current assets	630.74	590.99
2	**Current assets**		
a	Inventories	107.30	129.48
b	Financial assets		
i	Trade receivables	160.08	118.29
ii	Cash and cash equivalents	1.80	3.22
iii	Bank balances other than cash and cash equivalents	52.16	66.05
iv	Loans	0.19	0.38
v	Other financial assets	11.10	2.64
c	Other current assets	13.23	18.81
	Total current assets	345.86	338.87
	TOTAL ASSETS	**976.60**	**929.86**
B	**EQUITY AND LIABILITIES:**		
1	**Equity**		
a	Equity share capital	61.16	61.16
b	Other equity	598.49	545.18
	Total equity	659.65	606.34
	Liabilities		
2	**Non-current liabilities**		
a	Financial liabilities		
i	Borrowings	-	16.00
ii	Lease liabilities	20.28	21.02
b	Provisions	44.36	38.61
c	Deferred tax liabilities (net)	9.93	8.30
	Total non-current liabilities	74.57	83.93
3	**Current liabilities**		
a	Financial liabilities		
i	Borrowings	39.58	46.70
ii	Lease liabilities	2.85	2.52
iii	Trade payables		
	- total outstanding dues of micro enterprises and small enterprises	6.83	2.91
	- total outstanding dues of creditors other than micro enterprise and small enterprise	133.92	140.61
iv	Other financial liabilities	4.67	4.77
b	Other current liabilities	10.66	8.37
c	Provisions	30.00	27.39
d	Current tax liabilities (net)	13.87	6.32
	Total current liabilities	242.38	239.59
	Total liabilities	316.95	323.52
	TOTAL EQUITY AND LIABILITIES	**976.60**	**929.86**

For Identification Purposes Only * DELOITTE HASKINS & SELLS LLP * CHARTERED ACCOUNTANTS * MUMBAI * For Identification Purposes Only

CORONA Remedies Limited AHMEDABAD

Unaudited Statement of Consolidated Cash Flows for the Half Year ended 30 September 2025
(Amount Rs. in Crores)

Particulars	For Half Year ended Sept.2025 (Unaudited)	For Half Year ended Sept.2024 (Unaudited) (Refer note 4)
Cash flow from operating activities		
Profit before tax	130.47	96.63
Adjustments for:		
Share of loss / (profit) from Associate	0.03	0.01
Depreciation and amortization expenses	18.12	17.43
Finance costs	3.92	6.02
Interest income	(2.76)	(2.75)
Fair valuation adjustments of Investments designated as Fair Value through Profit & Loss (FVTPL)	(0.04)	(0.01)
Loss on sale/disposal of fixed assets	0.43	0.06
Provision for expected credit loss*	0.05	0.00
Provision for inventory obsolescence written back	(1.03)	(0.47)
Bad debts written off	0.05	0.01
Liabilities written back	(0.06)	(0.12)
Provision for expiry and breakage sales return	4.83	4.11
Net Unrealized exchange Gain	(0.24)	(0.04)
Operating profit before working capital changes	**153.77**	**120.88**
Changes in working capital		
Decrease/ (Increase) in inventories	23.22	(8.30)
Increase in trade receivables	(41.66)	(26.77)
Decrease / (Increase) in other current assets	5.58	(0.36)
Increase in other financial assets	(8.51)	(0.12)
Decrease in non-current assets	0.04	0.15
Decrease in loans	0.21	0.24
Increase in other financial liabilities	0.96	0.64
Increase in provisions	2.86	1.51
(Decrease) / Increase in trade payables	(2.72)	25.26
Increase in other current liabilities	2.29	7.28
Cash generated from operations	**136.04**	**120.41**
Income taxes paid (Net)	(22.60)	(15.64)
Net cash generated from operating activities (A)	**113.44**	**104.77**
Cash flow from Investing activities		
Payment for property, plant and equipment and intangible assets including capital work-in-progress, capital advance and capital payable	(32.51)	(40.80)
Proceeds from sale/ disposal of fixed assets	0.47	0.20
Fixed deposits placed with Bank not considered as Cash and cash equivalents-Net	(12.04)	15.31
Interest received	2.76	2.75
Net cash (used in) investing activities (B)	**(41.32)**	**(22.54)**
Cash flow from Financing activities		
Payment of dividend	(44.71)	(22.63)
Repayment of long-term borrowings	(18.00)	(33.00)
Net decrease in working capital borrowings	(5.11)	(19.87)
Interest paid	(3.27)	(4.84)
Payment towards lease liability (excluding interest)	(1.37)	(1.14)
Interest on lease liability	(1.09)	(1.18)
Net cash (used in) from financing activities (C)	**(73.55)**	**(82.66)**
Net (decrease) in cash and cash equivalents (A+B+C)	**(1.43)**	**(0.43)**
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents**	0.01	0.00
Cash and cash equivalents at the beginning of the period	**3.22**	**3.16**
Cash and cash equivalents at the end of the period	**1.80**	**2.73**

* Provision for expected credit loss for half year ended September 2024 represents amounting Rs.30,000/-

**Effect of exchange differences on restatement of foreign currency Cash and cash equivalents for half year ended September 2024 represents amounting Rs.33,835/-

Particulars	For Half Year ended Sept.2025 (Unaudited)	For Half Year ended Sept.2024 (Unaudited) (Refer note 4)
Cash and cash equivalents comprise		
Balances with banks:		
In current accounts	0.30	0.24
Cheques on hand	1.45	2.29
Cash on hands	0.05	0.20
Total cash and bank balances at end of the period	**1.80**	**2.73**

For Identification Purposes Only
CHARTERED ACCOUNTANTS
MUMBAI
CORONA Remedies Limited
AHMEDABAD

Notes to unaudited consolidated financial results for the Quarter and Half Year ended 30 September 2025 :

1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders.

As the Company's equity shares were listed on 15 December 2025, this statement of unaudited consolidated financial results for the quarter and half year ended 30 September 2025 is prepared for the first time in compliance with Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.

2 The above unaudited consolidated financial results of CORONA Remedies Limited [the 'Company'] and its associate have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 02 January 2026. The Statutory Auditors have carried out limited review of the aforesaid results.

3 These unaudited consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.

4 The financial results for the quarter ended 30 September 2024 and the half year ended 30 September 2024 have not been subject to limited review. However the management has exercised necessary diligence to ensure that the financial results for those periods provide a true and fair view of the Company's affairs.

5 The consolidated financial results for the quarter ended 30 June 2025 have been extracted from the audited special purpose interim financial statements which were prepared for IPO filings.

6 The Company and its associate has only one reportable business segment i.e. 'Pharmaceuticals'.

7 The Ministry of Labour& Employment (MoLE), Government of India, has announced the implementation of four Labour Codes viz. the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020 and the Occupational Safety, Health and Working Conditions Code, 2020 (Collectively "The Labour Codes"), effective 21 November 2025. The Company and its associate are in the process of assessing the impact of such changes. Since the Labour Codes are effective from 21 November 2025, they do not have any implication on the results for the quarter and half year ended 30 September 2025.

For CORONA Remedies Limited,

Nirav K. Mehta
Managing Director & CEO
DIN : 01644041

Place: Ahmedabad
Date : 02 January 2026

CORONA Remedies Limited AHMEDABAD

For Identification Purposes Only * DELOITTE HASKINS & SELLS LLP * CHARTERED ACCOUNTANTS * MUMBAI * For Identification Purposes Only